Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal

Fineline Cube Dec 31, 2025
Company Deals

NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion

Fineline Cube Dec 31, 2025
Company Deals

Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China

Fineline Cube Dec 31, 2025
Company Deals

Ribo Life Science Raises HK$1.6 Billion in Hong Kong IPO for siRNA Pipeline

Fineline Cube Dec 31, 2025
Company Deals

Broncus Medical Acquires Valgen Stake from Venus for $15 Million

Fineline Cube Dec 30, 2025
Policy / Regulatory

Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders

Fineline Cube Dec 30, 2025
Company Drug

HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review

Fineline Cube Dec 31, 2025
Company Drug

Sirius Therapeutics Doses First Phase II Patient for SRSD216 siRNA Hyperlipoproteinemia Therapy

Fineline Cube Dec 31, 2025
Company Deals

Boehringer Ingelheim Partners with Wuhan Union Hospital to Enhance Clinical Research and Development

Fineline Cube Nov 8, 2024

Boehringer Ingelheim, a leading German pharmaceutical company, has entered into a strategic partnership with Wuhan...

Policy / Regulatory

NHSA and MCA Boost Medical Assistance with Enhanced Information Sharing Measures

Fineline Cube Nov 8, 2024

The National Healthcare Security Administration (NHSA) and the Ministry of Civil Affairs (MCA) have jointly...

Company Deals

Hainan Haiyao Enters JV with Haikou and Xenios AG to Advance ECMO Technology

Fineline Cube Nov 8, 2024

Hainan Haiyao Co., Ltd (SHE: 000566), a prominent Chinese company, has announced the signing of...

Company Drug

Belief BioMed’s BBM-D101 Receives FDA Orphan Drug and Pediatric Rare Disease Designations for DMD

Fineline Cube Nov 7, 2024

Belief BioMed has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan...

Company Deals

Nanjing Leads Biolabs and Aditum Bio Launch Oblenio Bio with Focus on CD19 Tri-Specific Antibody

Fineline Cube Nov 7, 2024

China-based Nanjing Leads Biolabs Co., Ltd and venture capital firm Aditum Bio have announced the...

Company Deals

Sanofi and Cathay Capital Forge Partnership to Boost Sino-French Pharmaceutical Cooperation

Fineline Cube Nov 7, 2024

French pharmaceutical giant Sanofi (NASDAQ: SNY) has signed a partnership deal with Cathay Capital, a...

Company Deals

Eisai and GE Healthcare Sign MoU at CIIE to Collaborate on Alzheimer’s Disease Solutions

Fineline Cube Nov 7, 2024

At the 7th China International Import Expo (CIIE), Japan-based Eisai Co., Ltd (TYO: 4523) entered...

Company Deals

Lohmann & Rauscher Partners with Allmed Medical Products at CIIE for Medical Dressings

Fineline Cube Nov 7, 2024

Lohmann & Rauscher, a medical group with headquarters in Germany and Austria, has entered into...

Company

I-Mab Appoints Sean (Xi-Yong) Fu as Permanent CEO, Effective November 1, 2024

Fineline Cube Nov 7, 2024

US-based biopharmaceutical company I-Mab (NASDAQ: IMAB) has announced the appointment of Sean (Xi-Yong) Fu, PhD,...

Company

Novo Nordisk Reports Q3 2024 Financials with 24% YOY Revenue Growth

Fineline Cube Nov 7, 2024

Denmark-based pharmaceutical company Novo Nordisk A/S (NYSE: NVO) has released its financial results for the...

Company Deals

Shanghai Pharmaceutical Co., Ltd Secures Multiple Partnerships at CIIE

Fineline Cube Nov 7, 2024

At the 7th China International Import Expo (CIIE), China-based Shanghai Pharmaceutical Co., Ltd (SPH, SHA:...

Company Medical Device

Siemens Healthineers AG Reports Fiscal 2024 Results with Targeted Revenue Growth

Fineline Cube Nov 7, 2024

Germany-based medical device giant Siemens Healthineers AG (ETR: SHL) has released its financial results for...

Company Drug

HutchMed to Present Updated Data from Solvleplenib ESLIM-01 Phase III Trial at ASH and ESMO Congress 2024

Fineline Cube Nov 7, 2024

China-based HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced plans to present new and...

Company Deals

Bayer HealthCare Partners with China Population Welfare Foundation at CIIE for Public Health Initiatives

Fineline Cube Nov 7, 2024

German pharmaceutical giant Bayer HealthCare (FRA: BAYN) has entered into a partnership agreement with the...

Company Deals

Medtronic Partners with China Resources Guangdong Pharmaceutical at CIIE for Medical Equipment Development

Fineline Cube Nov 7, 2024

US-Irish firm Medtronic (NYSE: MDT) has entered into a partnership with China-based China Resources Guangdong...

Company Drug

Pfizer’s Talzenna (talazoparib) Approved by China’s NMPA for mCRPC Treatment

Fineline Cube Nov 7, 2024

The National Medical Products Administration (NMPA) website has indicated that Pfizer’s (NYSE: PFE) marketing filing...

Company Drug

Shouyao Holdings Adjusts Development Strategy for SY-1530, Halts Monotherapy Clinical Trials

Fineline Cube Nov 7, 2024

Beijing-based Shouyao Holdings (Beijing) Co., Ltd (SHA: 688197) has announced a strategic adjustment regarding its...

Company Drug

Nanjing Leads Biolabs Secures FDA Orphan Drug Designation for LBL-034 in Multiple Myeloma Treatment

Fineline Cube Nov 7, 2024

Nanjing Leads Biolabs Co., Ltd, a China-based biopharmaceutical company, has announced that it has received...

Company Drug

Sanofi’s Dupixent Gains EMA Approval for Eosinophilic Esophagitis in Children

Fineline Cube Nov 7, 2024

French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced that it has received marketing approval from...

Company Deals

Novartis Forges Partnerships at CIIE to Strengthen Radioligand Therapy Ecosystem in China

Fineline Cube Nov 7, 2024

At the 7th China International Import Expo (CIIE), Swiss pharmaceutical giant Novartis (NYSE: NVS) announced...

Posts pagination

1 … 208 209 210 … 603

Recent updates

  • Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal
  • HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review
  • NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion
  • Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China
  • Sirius Therapeutics Doses First Phase II Patient for SRSD216 siRNA Hyperlipoproteinemia Therapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal

Company Drug

HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review

Company Deals

NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion

Company Deals

Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.